depression
BrainsWay Announces FDA Approval of Neurolief's ProlivTMRx Neuromodulation System for Major Depressive Disorder (MDD)
BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for Neurolief's ProlivTMRx system, a Class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder (MDD) who have failed to achieve satisfactory im
CCHR Calls On FDA To Act As Evidence Mounts Linking Antidepressants To Persistent Sexual Dysfunction
(MENAFN - Send2Press Newswire) LOS ANGELES, Calif., Jan. 12, 2026 (SEND2PRESS NEWSWIRE) - The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, is ...
Opinion: Do Americans expect too much from drugs?
Do Americans expect too much from drugs?
Tris Pharma Announces Acceptance Of New Publication Highlighting Promise Of Dual NOP-MOP (Dual-NMR) Agonists For The Treatment Of Moderate-To-Severe Pain
(MENAFN - GlobeNewsWire - Nasdaq) – Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction ...
Opinion: RFK Jr.’s war on antidepressants is coming — and it will cost lives
“Kennedy’s antidepressant rhetoric is not only based on bad science, it fuels distrust in mental health treatments” in the midst of a crisis for adolescents, experts write.
Bright Minds Biosciences Announces Positive Topline Results From Phase 2 Clinical Trial Of BMB-101 In Patients With Absence Seizures And Developmental And Encephalopathic Epilepsies (DEE)
(MENAFN - GlobeNewsWire - Nasdaq) BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of ...
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of ...
Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo® Transcranial Magnetic Stimulation (TMS) machines nationwide.Program will unite common treatment protocols and clinical training with neurocare expertise in neuromodulation technology and...
Cyclerion Therapeutics Announces Strategic Agreement With Medsteer And Progress Toward Initiating Phase 2 Proof-Of-Concept Study For CYC-126 In Treatment-Resistant Depression
(MENAFN - GlobeNewsWire - Nasdaq) – Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and ...
The debate about whether the NHS should use magic mushrooms to treat depression
Many clinical trials to test the use of psychedelic medicines for conditions such as depression have been underway since 2022 - with surprising results
FDA panelists questioned antidepressants in pregnancy. But doctors call them a lifeline.
Medical experts are concerned that a July panel discussion convened by the FDA could lead to more cases of untreated depression during or after pregnancy.
Mom credits breakthrough drug for getting her through ‘hardest year' of her life
